Cite
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.
MLA
Allen, Larry A., et al. “Liver Function Abnormalities and Outcome in Patients with Chronic Heart Failure: Data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.” European Journal of Heart Failure, vol. 11, no. 2, Feb. 2009, pp. 170–77. EBSCOhost, https://doi.org/10.1093/eurjhf/hfn031.
APA
Allen, L. A., Felker, G. M., Pocock, S., McMurray, J. J. V., Pfeffer, M. A., Swedberg, K., Duolao Wang, Yusuf, S., Michelson, E. L., & Granger, C. B. (2009). Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure, 11(2), 170–177. https://doi.org/10.1093/eurjhf/hfn031
Chicago
Allen, Larry A., G. Michael Felker, Stuart Pocock, John J. V. McMurray, Marc A. Pfeffer, Karl Swedberg, Duolao Wang, Salim Yusuf, Eric L. Michelson, and Christopher B. Granger. 2009. “Liver Function Abnormalities and Outcome in Patients with Chronic Heart Failure: Data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.” European Journal of Heart Failure 11 (2): 170–77. doi:10.1093/eurjhf/hfn031.